WHWK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Whitehawk Therapeutics Inc. (WHWK) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows potential in its ADC pipeline and has positive analyst coverage, the lack of immediate catalysts, weak financial performance, and neutral technical indicators suggest holding off on investment until more favorable conditions emerge.
The MACD is negatively expanding (-0.0638), RSI is neutral at 36.093, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 3.473), but the lack of bullish momentum suggests a cautious approach.
Hedge funds are significantly increasing their positions (+230.74% last quarter). Analyst coverage is positive, with Oppenheimer initiating an Outperform rating and a $6 price target, citing promising ADC pipeline developments. Gross margin improved slightly to 89.36%.
The company reported zero revenue in Q4 2025, with a net loss of -$23.25M. Technical indicators are neutral to bearish, and no recent news or significant insider trading activity is present. Congress trading data is also absent.
In Q4 2025, revenue dropped to $0 (-100% YoY), while net income improved to -$23.25M (+27.24% YoY). EPS increased to -2.25 (+235.82% YoY), and gross margin slightly improved to 89.36%. Despite some improvements, the financials remain weak overall.
Oppenheimer initiated coverage with an Outperform rating and a $6 price target, highlighting the company's promising ADC pipeline and ongoing Phase 1 trials for HWK-007 in non-small cell lung cancer and ovarian cancer.
